Regulatory FDA weighs drug repurposing pathway for underserved diseases Pharmaceutical TechnologyApproved drugs could be expanded into disease areas with limited commercial potential, providing supporting data is available.Read full story pharminent May 12, 2026 (Last updated: May 16, 2026) Pharmaceutical Technology Approved drugs could be expanded into disease areas with limited commercial potential, providing supporting data is available. Read full story Post navigation Previous: Pharma’s manufacturing reconfigurations provide CDMOs with expansion opportunitiesNext: A year after Vertex’s big launch, pain drug research faces a pivotal moment Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
